Key Points
-
Current therapy for diabetic kidney disease is based on blood pressure control and the antialbuminuric and antihypertensive effects of renin–angiotensin system (RAS) blockers
-
Diabetic kidney disease remains the most common cause of end-stage renal disease, indicating the need for additional therapeutic approaches beyond the RAS
-
In the past few years, several major trials have failed to show a favourable risk to benefit ratio of promising novel therapeutic approaches to diabetic kidney disease
-
Insufficient understanding of drug mechanisms and the pathogenesis of diabetic kidney disease, lack of a gold standard for diagnosis, heterogeneity of trial populations and a paucity of hard outcomes might underlie these failures
-
Ongoing clinical trials are testing novel approaches that target signalling pathways, inflammation and fibrosis in diabetic kidney disease
-
Unfortunately, the primary outcome of most of these trials is albuminuria (which might be dissociated from loss of renal function) or estimated glomerular filtration rate (GFR), which might not adequately represent actual GFR
Abstract
Despite improvements in glycaemic and blood pressure control, and the efficacy of renin–angiotensin system (RAS) blockade for proteinuria reduction, diabetic nephropathy is the most frequent cause of end-stage renal disease in developed countries. This finding is consistent with the hypothesis that key pathogenetic mechanisms leading to progression of renal disease are not modified or inactivated by current therapeutic approaches. Although extensive research has elucidated molecular signalling mechanisms that are involved in progression of diabetic kidney disease, a number of high-profile clinical trials of potentially nephroprotective agents have failed, highlighting an insufficient understanding of pathogenic pathways. These include trials of paricalcitol in early diabetic kidney disease and bardoxolone methyl in advanced-stage disease. Various strategies based on encouraging data from preclinical studies that showed renoprotective effects of receptor antagonists, neutralizing antibodies, kinase inhibitors, small compounds and peptide-based technologies are currently been tested in randomized controlled trials. Phase II clinical trials are investigating approaches targeting inflammation, fibrosis and signalling pathways. However, only one trial that aims to provide evidence for marketing approval of a potentially renoprotective drug (atrasentan) is underway—further research into the potential nephroprotective effects of novel glucose-lowering agents is required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
WHO. Diabetes fact sheet N°312. WHO Media Centre [online], (2013).
Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).
Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302–308 (2013).
Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229–234 (1998).
KDIGO BP Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2, 337–414 (2012).
American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 37 (Suppl. 1), S14–S80 (2014).
Fernandez-Fernandez. B. et al. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med. 103, 219–234 (2012).
Collins, A. J. et al. US renal data system 2013 annual data report. Am. J. Kidney Dis. 63, A7 (2014).
Kussman, M. J., Goldstein, H. & Gleason, R. E. The clinical course of diabetic nephropathy. JAMA 236, 1861–1863 (1976).
Adler, A. I. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63, 225–232 (2003).
de Boer, I. H. et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch. Intern. Med. 171, 412–420 (2011).
Molitch, M. E. et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33, 1536–1543 (2010).
Kramer, H. J., Nguyen, Q. D., Curhan, G. & Hsu, C. Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289, 3273–3277 (2003).
Haller, H. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med. 364, 907–917 (2011).
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I. & Holman, R. R. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55, 1832–1839 (2006).
Garg, A. X., Kiberd, B. A., Clark, W. F., Haynes, R. B. & Clase, C. M. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 61, 2165–2175 (2002).
Dwyer, J. P. et al. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study. Cardiorenal. Med. 2, 1–10 (2012).
Dwyer, J. P. & Lewis, J. B. Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. Med. Clin. North Am. 97, 53–58 (2013).
MacIsaac, R. J. et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 29, 1560–1566 (2006).
Caramori, M. L., Fioretto, P. & Mauer, M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52, 1036–1040 (2003).
Ekinci, E. I. et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 36, 3620–3626 (2013).
Wolkow, P. P. et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J. Am. Soc. Nephrol. 19, 789–797 (2008).
Ficociello, L. H. et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33, 1337–1343 (2010).
Perlstein, T. S. et al. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 66, 1465–1470 (2004).
Rosolowsky, E. T. et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin. J. Am. Soc. Nephrol. 3, 706–713 (2008).
Justo, P., Sanz, A. B., Egido, J. & Ortiz, A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 54, 2424–2429 (2005).
Sanchez-Nino, M. D. et al. BASP1 promotes apoptosis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 610–621 (2010).
Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547–553 (2008).
de Zeeuw, D. et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543–1551 (2010).
Kohan, D. E. et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol. 22, 763–772 (2011).
Lewis, E. J. et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am. J. Kidney Dis. 58, 729–736 (2011).
Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327–336 (2011).
Tumlin, J. A., Galphin, C. M. & Rovin, B. H. Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J. Diabetes Res. 2013, 489869 (2013).
Tuttle, K. R. et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686–2690 (2005).
Mauer, M. et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 361, 40–51 (2009).
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am. J. Kidney Dis. 60, 850–886 (2012).
Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).
Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 49 (Suppl. 2), S12–S154 (2007).
ACCORD Study Group et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
Onuigbo, M. A. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin. Pract. 118, c407–c419 (2011).
Goncalves, A. R., Khwaja, A., Ahmed, A. K., El Kossi, M. & El Nahas, M. Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response. Nephron Clin. Pract. 119, c348–c354 (2011).
KIDGO. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 3, 259–305 (2013).
The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 47, 1703–1720 (1995).
DCCT/EDIC Research Group et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 365, 2366–2376 (2011).
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342, 381–389 (2000).
de Boer, I. H. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37, 24–30 (2014).
Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
Perkovic, V. et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517–523 (2013).
Daniels, M. et al. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. Diabetes Care 36, 2639–2645 (2013).
Martin, J. H., Deacon, C. F., Gorrell, M. D. & Prins, J. B. Incretin-based therapies—review of the physiology, pharmacology and emerging clinical experience. Intern. Med. J. 41, 299–307 (2011).
Gerich, J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res. Clin. Pract. 90, 131–140 (2010).
Finan, B. et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 5, 209ra151 (2013).
Muskiet, M. H., Smits, M. M., Morsink, L. M. & Diamant, M. The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? Nat. Rev. Nephrol. 10, 88–103 (2013).
Alter, M. L. et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press. Res. 36, 119–130 (2012).
Schernthaner, G. et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 14, 470–478 (2012).
Groop, P. H. et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36, 3460–3468 (2013).
Fujita, H. et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr. J. 61, 159–166 (2014).
Ayaori, M. et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J. Am. Heart Assoc. 2, e003277 (2013).
Rossi, M. C. et al. Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND study. Nutr. Metab. Cardiovasc. Dis. 20, 110–116 (2010).
Friedman, A. N., Chambers, M., Kamendulis, L. M. & Temmerman, J. Short-term changes after a weight reduction intervention in advanced diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 8, 1892–1898 (2013).
Morales, E., Valero, M. A., Leon, M., Hernandez, E. & Praga, M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am. J. Kidney Dis. 41, 319–327 (2003).
Neff, K. J. et al. The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. Nephrol. Dial. Transplant. 28 (Suppl. 4), iv73–iv82 (2013).
Solano, M. P. & Goldberg, R. B. Management of dyslipidemia in diabetes. Cardiol. Rev. 14, 125–135 (2006).
Stone, N. J. et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a.
Tonkin, A. M. & Chen, L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122, 850–852 (2010).
Abe, M. et al. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J. Atheroscler. Thromb. 18, 1018–1028 (2011).
Kimura, S. et al. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes. Metab. 14, 666–669 (2012).
Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).
Ting, R. D. et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care 35, 218–225 (2012).
ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
Bonds, D. E. et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 55, 1641–1650 (2012).
Ruiz, S., Pergola, P. E., Zager, R. A. & Vaziri, N. D. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83, 1029–1041 (2013).
Hong, D. S. et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396–3406 (2012).
Yoh, K. et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 13, 1159–1170 (2008).
Jiang, T. et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59, 850–860 (2010).
Zheng, H. et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60, 3055–3066 (2011).
Zoja, C. et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Renal Physiol. 304, F808–F819 (2013).
Chin, M. et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am. J. Physiol. Renal Physiol. 304, F1438–F1446 (2013).
Zoja, C., Benigni, A. & Remuzzi, G. The Nrf2 pathway in the progression of renal disease. Nephrol. Dial. Transplant. 29 (Suppl. 1), i19–i24 (2013).
de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098–1107 (2012).
Rojas-Rivera, J., De La Piedra, C., Ramos, A., Ortiz, A. & Egido, J. The expanding spectrum of biological actions of vitamin D. Nephrol. Dial. Transplant. 25, 2850–2865 (2010).
Gonzalez-Parra, E. et al. Vitamin D receptor activation and cardiovascular disease. Nephrol. Dial. Transplant. 27 (Suppl. 4), iv17–iv21 (2012).
Sanchez-Nino, M. D. et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 302, F647–F657 (2012).
Perez-Gomez, M. V., Ortiz-Arduan, A. & Lorenzo-Sellares, V. Vitamin D and proteinuria: a critical review of molecular bases and clinical experience. Nefrologia 33, 716–726 (2013).
Alborzi, P. et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52, 249–255 (2008).
Fishbane, S. et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 54, 647–652 (2009).
Gonzalez, E. et al. Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation 95, e49–e52 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Perez, A., Raab, R., Chen, T. C., Turner, A. & Holick, M. F. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. 134, 1070–1078 (1996).
Fernandez-Fernandez, B. et al. Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis? BMC. Nephrol. 13, 21 (2012).
Ortiz, A., Sanchez Nino, M. D., Rojas, J. & Egido, J. Paricalcitol for reduction of albuminuria in diabetes. Lancet 377, 635–636 (2011).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US Department of Health and Human Services. Orange Book: approved drug products with therapeutic equivalence evaluations. US Food and Drug Administration [online], (2014).
Ramasamy, R., Yan, S. F. & Schmidt, A. M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul. Pharmacol. 57, 160–167 (2012).
Kim, J. H., Hong, C. O., Koo, Y. C., Kim, S. J. & Lee, K. W. Oral administration of ethyl acetate-soluble portion of Terminalia chebula conferring protection from streptozotocin-induced diabetic mellitus and its complications. Biol. Pharm. Bull. 34, 1702–1709 (2011).
Bolton, W. K. et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32–40 (2004).
[No authors listed] Alteon may drop pimagedine in NIDDM. thepharmaletter [online], (1998).
Lewis, E. J. et al. Pyridorin in type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 131–136 (2012).
Williams, M. E. et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am. J. Nephrol. 27, 605–614 (2007).
Ceol, M. et al. Glycosaminoglycan therapy prevents TGF-β1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J. Am. Soc. Nephrol. 11, 2324–2336 (2000).
Gambaro, G. et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615–1625 (2002).
Packham, D. K. et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123–130 (2012).
Bhattacharya, S., Manna, P., Gachhui, R. & Sil, P. C. D-saccharic acid 1,4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling. Toxicol. Appl. Pharmacol. 267, 16–29 (2013).
Sharma, S., Kulkarni, S. K. & Chopra, K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin. Exp. Pharmacol. Physiol. 33, 940–945 (2006).
Ndisang, J. F. & Jadhav, A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. Endocrinology 155, 215–229 (2014).
Wang, G. G., Lu, X. H., Li, W., Zhao, X. & Zhang, C. Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid . Based Complement. Alternat. Med. 2011, 323171 (2011).
Khazim, K., Gorin, Y., Cavaglieri, R. C., Abboud, H. E. & Fanti, P. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am. J. Physiol. Renal Physiol. 305, F691–F700 (2013).
Sedeek, M. et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of type 2 diabetes. Clin. Sci. (Lond.) 124, 191–202 (2013).
Thallas-Bonke, V. et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 57, 460–469 (2008).
Winiarska, K., Szymanski, K., Gorniak, P., Dudziak, M. & Bryla, J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 91, 261–270 (2009).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Tepel, M. et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343, 180–184 (2000).
Rasi, H. S. et al. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus. Iran. J. Kidney Dis. 6, 39–43 (2012).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Fallahzadeh, M. K. et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am. J. Kidney Dis. 60, 896–903 (2012).
US National Library of Medicine. ClinicalTrials.gov[online], (2012).
Budhiraja, S. & Singh, J. Protein kinase C β inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam. Clin. Pharmacol. 22, 231–240 (2008).
Gilbert, R. E. et al. Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 30, 995–996 (2007).
[No authors listed] Ruboxistaurin: LY 333531. Drugs R. D. 8, 193–199 (2007).
European Medicines Agency. Withdrawal assessment report for ARXXANT (Ruboxistaurin (as mesilate monohydrate) EMEA/H/C/753. European Medicines Agency [online], (2007).
Tuttle, K. R. et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol. 2, 631–636 (2007).
Sharma, K. et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol. 22, 1144–1151 (2011).
Adler, S. G. et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420–1428 (2010).
US National Library of Medicine. ClinicalTrials.gov[online], (2012).
Kohan, D. E. & Pollock, D. M. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br. J. Clin. Pharmacol. 76, 573–579 (2013).
Gómez-Garre, D. et al. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 50, 962–972 (1996).
Gómez-Garre, D. et al. Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 37, 1171–1178 (2001).
Rodriguez-Vita, J. et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells. Circ. Res. 97, 125–134 (2005).
Mann, J. F. et al. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527–535 (2010).
Kohan, D. E., Cleland, J. G., Rubin, L. J., Theodorescu, D. & Barton, M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 91, 528–539 (2012).
Safdar, Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vasc. Health Risk Manag. 7, 119–124 (2011).
Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Andress, D. L. et al. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci. 91, 739–742 (2012).
Brem, A. S., Morris, D. J. & Gong, R. Aldosterone-induced fibrosis in the kidney: questions and controversies. Am. J. Kidney Dis. 58, 471–479 (2011).
Morales, E. et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol. Dial. Transplant. 28, 405–412 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
PRIORITY Consortium. EU Priority [online], (2014).
Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388–1393 (2010).
Maahs, D. M. et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr. Diab. Rep. 13, 550–559 (2013).
Becker, M. A., MacDonald, P. A., Hunt, B. J. & Jackson, R. L. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes. Metab. 15, 1049–1055 (2013).
Hosoya, T. et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials 15, 26 (2014).
Ziyadeh, F. N. Different roles for TGF-β and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy. Diabetes Res. Clin. Pract. 82 (Suppl. 1), S38–S41 (2008).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Castoldi, G. et al. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Am. J. Nephrol. 37, 65–73 (2013).
Russo, L. M., del Re, E., Brown, D. & Lin, H. Y. Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-β type II receptor. Diabetes 56, 380–388 (2007).
Han, D. C., Hoffman, B. B., Hong, S. W., Guo, J. & Ziyadeh, F. N. Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am. J. Physiol Renal Physiol. 278, F628–F634 (2000).
Navarro-González, J. F., Mora-Fernández, C., Muros de, F. M. & García-Pérez, J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7, 327–340 (2011).
Shan, D. et al. Pentoxifylline for diabetic kidney disease. Cochra ne Database of Systematic Reviews, Issue 2. Art. No.: CD006800. http://dx.doi.org/10.1002/14651858.CD006800.pub2.
Ghorbani, A., Omidvar, B., Beladi-Mousavi, S. S., Lak, E. & Vaziri, S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 32, 790–796 (2012).
Navarro-Gonzalez, J. F. et al. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J. Diabetes Complications 25, 314–319 (2011).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Moreno, J. A. et al. Targeting chemokines in proteinuria-induced renal disease. Expert. Opin. Ther. Targets 16, 833–845 (2012).
Sayyed, S. G. et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int. 80, 68–78 (2011).
Sullivan, T. et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am. J. Physiol. Renal Physiol. 305, F1288–F1297 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Tan, R. J. & Liu, Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am. J. Physiol. Renal Physiol. 302, F1351–F1361 (2012).
Gooz, M. ADAM-17: the enzyme that does it all. Crit Rev. Biochem. Mol. Biol. 45, 146–169 (2010).
Williams, J. M. et al. Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 300, F983–F998 (2011).
Abboud, H. et al. Effect of protease inhibition by XL784 in patients (Pts) with diabetic nephropathy (DN) [abstract F-PO1030]. Presented at ASN Kidney Week 2007, San Francisco.
Aggarwal, H. K. et al. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy. Ren. Fail. 32, 941–946 (2010).
Sanz, A. B. et al. NF-κB in renal inflammation. J. Am. Soc. Nephrol. 21, 1254–1262 (2010).
Kim, J. E. et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS ONE 8, e62068 (2013).
Gui, D. et al. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression. Cytokine 61, 970–977 (2013).
Mora, E., Guglielmotti, A., Biondi, G. & Sassone-Corsi, P. Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway. Cell Cycle 11, 159–169 (2012).
Ble, A. et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am. J. Nephrol. 34, 367–372 (2011).
Ruggenenti, P. Effects of MCP-1 inhibition by bindarit therapy in type 2 diabetes subjects with micro- or macro-albuminuria. J. Am. Soc. Nephrol. 21, F–FC194 (2010).
Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469–477 (2009).
Fernández-Sánchez, R. et al. AG490 promotes HIF-1α accumulation by inhibiting its hydroxylation. Curr. Med. Chem. 19, 4014–4023 (2012).
Miyata, T., Suzuki, N. & van Ypersele de Strihou, C. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology? Kidney Int. 84, 693–702 (2013).
Banes, A. K. et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am. J. Physiol. Renal Physiol. 286, F653–F659 (2004).
Taira, M. et al. Treatment of streptozotocin-induced diabetes mellitus in rats by transplantation of islet cells from two major histocompatibility complex disparate rats in combination with intra bone marrow injection of allogeneic bone marrow cells. Transplantation 79, 680–687 (2005).
Ortiz-Muñoz, G. et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J. Am. Soc. Nephrol. 21, 763–772 (2010).
Taylor, P. et al. A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study. Ann. Rheum. Dis. 73 (Suppl. 1), A31 (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Burstein, A. H. et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC. Neurol. 14, 12 (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2009).
Gross, M. L. et al. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab Invest. 86, 262–274 (2006).
Park, S. Y. et al. Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes. Endocr. J. 59, 709–716 (2012).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Hodgetts, S. I., Simmons, P. J. & Plant, G. W. Human mesenchymal precursor cells (Stro-1+) from spinal cord injury patients improve functional recovery and tissue sparing in an acute spinal cord injury rat model. Cell Transplant. 22, 393–412 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Houtgraaf, J. H. et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ. Res. 113, 153–166 (2013).
Eller, K. et al. Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 60, 2954–2962 (2011).
Zheng, D. et al. Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp. Nephrol. 118, e87–e99 (2011).
Lin, M. et al. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int. 83, 887–900 (2013).
Lopez-Parra, V. et al. Fcγ receptor deficiency attenuates diabetic nephropathy. J. Am. Soc. Nephrol. 23, 1518–1527 (2012).
Sugimoto, H. et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46, 2075–2081 (1997).
Moriwaki, Y. et al. Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 44, 215–218 (2007).
Gupta-Ganguli, M., Cox, K., Means, B., Gerling, I. & Solomon, S. S. Does therapy with anti-TNF-α improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care 34, e121 (2011).
Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705–715 (2008).
Sugimoto, H. et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18, 396–404 (2012).
Ka, S. M. et al. Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 55, 509–519 (2012).
Putta, S. et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 23, 458–469 (2012).
Long, J., Wang, Y., Wang, W., Chang, B. H. & Danesh, F. R. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J. Biol. Chem. 286, 11837–11848 (2011).
Taniguchi, K. et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 62, 3874–3886 (2013).
Elmarakby, A. A. et al. Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice. Vascul. Pharmacol. 55, 149–156 (2011).
Lassila, M. et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 16, 363–373 (2005).
Kolavennu, V., Zeng, L., Peng, H., Wang, Y. & Danesh, F. R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57, 714–723 (2008).
Xie, X. et al. Activation of RhoA/ROCK regulates NF-κB signaling pathway in experimental diabetic nephropathy. Mol. Cell Endocrinol. 369, 86–97 (2013).
Jung, D. S. et al. FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells. Am. J. Physiol. Renal Physiol. 295, F595–F604 (2008).
Ijaz, A. et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int. 75, 381–388 (2009).
Lim, A. K. et al. Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats. Am. J. Nephrol. 34, 337–346 (2011).
Kim, S. H. et al. The reno-protective effect of a phosphoinositide 3-kinase inhibitor wortmannin on streptozotocin-induced proteinuric renal disease rats. Exp. Mol. Med. 44, 45–51 (2012).
Durand, C. A. et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110δ opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity 46, 62–73 (2013).
Day, R. T., Cavaglieri, R. C. & Feliers, D. Apelin retards the progression of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 304, F788–F800 (2013).
Gil-Bernabe, P. et al. Exogenous activated protein C inhibits the progression of diabetic nephropathy. J. Thromb. Haemost. 10, 337–346 (2012).
Bock, F. et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc. Natl Acad. Sci. USA 110, 648–653 (2013).
Tak, E. et al. CD73-Dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy. J. Am. Soc. Nephrol. 25, 547–563 (2013).
Cárdenas, A. et al. Adenosine A(2B) receptor-mediated VEGF induction promotes diabetic glomerulopathy. Lab Invest. 93, 135–144 (2013).
Nam, D. H. et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153, 1387–1396 (2012).
Barutta, F. et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60, 2386–2396 (2011).
Tanaka, Y. et al. Autophagy as a therapeutic target in diabetic nephropathy. Exp. Diabetes Res. 2012, 628978 (2012).
Fang, L. et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS ONE 8, e60546 (2013).
Himmelfarb, J. & Tuttle, K. R. New therapies for diabetic kidney disease. N. Engl. J. Med. 369, 2549–2550 (2013).
Collins, F. S. Reengineering translational science: the time is right. Sci. Transl. Med. 3, 90cm17 (2011).
Thompson, A. Proteinuria as a surrogate end point—more data are needed. Nat. Rev. Nephrol. 8, 306–309 (2012).
Mischak, H. et al. Implementation of proteomic biomarkers: making it work. Eur. J. Clin. Invest 42, 1027–1036 (2012).
Gaspari, F. et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 84, 164–173 (2013).
de Zeeuw, D. The selective type A endothelin antagonist atrasentan reduces residual albuminuria in patients with type 2 diabetes and nephropathy. Presented at the 50th ERA–EDTA Congress (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2007).
Endo, K. et al. Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. J. Atheroscler. Thromb. 20, 494–502 (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Schjoedt, K. J. et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536–542 (2006).
Japanese Pharmaceutical Information Center. ClinicalTrials.jp[online], (2008).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2010).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2012).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Alkhalaf, A. et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33, 1598–1601 (2010).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Bell, J. et al. Results of a randomized trial to evaluate a novel rage inhibitor in patients with diabetic nephropathy [abstract 957-P], in 71st American Diabetes Association Scientific Sessions (2011).
Darisipudi, M. N. et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am. J. Pathol. 179, 116–124 (2011).
Kitada, M., Kume, S., Imaizumi, N. & Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60, 634–643 (2011).
Cetkovic-Cvrlje, M., Dragt, A. L., Vassilev, A., Liu, X. P. & Uckun, F. M. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin. Immunol. 106, 213–225 (2003).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
US National Library of Medicine. ClinicalTrials.gov[online], (2013).
Acknowledgements
This work was supported by grants from the Spanish Ministry of Science (SAF 2012-38830 to C.G.-G.), Fondo de Investigaciones Sanitarias (FIS PS09/00447, FIS 10/0072, PI13/00047, FIS/PIE13/00051, ISCIII-RETIC REDinREN/RD06/0016 and 12/0021), Spanish Society of Nephrology, Comunidad de Madrid S2010/BMD-2378 and PRIORITY as well as ISCIII Rio Hortega to B.F.-F., Programa Intensificación Actividad Investigadora (ISCIII/Agencia Laín-Entralgo/CM) to A.O., Fundacion Lilly and Diabetes kidney connect (Health-F2-2013-602422) to J.E.
Author information
Authors and Affiliations
Contributions
All authors researched the data for the article, wrote the manuscript, contributed to discussions of the content and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C. et al. Therapeutic approaches to diabetic nephropathy—beyond the RAS. Nat Rev Nephrol 10, 325–346 (2014). https://doi.org/10.1038/nrneph.2014.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.74
This article is cited by
-
An easy-to-operate web-based calculator for predicting the progression of chronic kidney disease
Journal of Translational Medicine (2021)
-
Evaluation of nephroprotective and cytotoxic effect of ethanolic extract of Mikania scandens leaves by using alloxan-induced diabetic nephropathy mice
Clinical Phytoscience (2020)
-
Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy
Laboratory Investigation (2018)
-
SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition
Laboratory Investigation (2018)
-
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update
Journal of Biomedical Science (2017)